Search research articles
Contact Us
Filters
Showing results (561-570 of 574) with videos related to
Page
of 58
Sort By:
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
World Journal of Urology
|
September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Sarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
World Journal of Urology
|
August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Urologic Oncology
|
February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
Genomics
|
December 12, 2001
Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine
L C McCarthy, D A Hosford, J H Riley, et al.
World Journal of Urology
|
June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy
N Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology
|
November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy
Anna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
European Urology
|
September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Homayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Page
of 58
Search research articles
Search
Showing results (561-570 of 574) with videos related to
Sort By:
Page
of 58
Urologic Oncology
|
December 13, 2023
Interruptions in bladder cancer care during the COVID-19 public health emergency
John L Gore, Kristin Follmer, Jason Reynolds, et al.
World Journal of Urology
|
September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Sarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
World Journal of Urology
|
August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
The Journal of Urology
|
May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 Trial
Vikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.
Urologic Oncology
|
February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
Genomics
|
December 12, 2001
Single-nucleotide polymorphism alleles in the insulin receptor gene are associated with typical migraine
L C McCarthy, D A Hosford, J H Riley, et al.
World Journal of Urology
|
June 9, 2018
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy
N Vasdev, H Zargar, J P Noël, et al.
Urologic Oncology
|
November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy
Anna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
European Urology
|
September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Homayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
The Lancet. Oncology
|
November 30, 2020
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial
Stephen A Boorjian, Mehrdad Alemozaffar, Badrinath R Konety, et al.
Page
of 58